Advertisement
Humacyte, Inc. (HUMA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
As of 01:26PM EST. Market open.
| Previous Close | 4.2800 |
| Open | 4.2400 |
| Bid | 4.3800 x 100 |
| Ask | 4.4000 x 100 |
| Day's Range | 4.1210 - 4.4105 |
| 52 Week Range | 2.4510 - 9.9700 |
| Volume | |
| Avg. Volume | 3,035,646 |
| Market Cap | 564.852M |
| Beta (5Y Monthly) | 1.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3400 |
| Earnings Date | Nov 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
GlobeNewswireHumacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will present Phase 3 results from a clinical study comparing efficacy and safety of Humacyte's acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in patients with end stage renal disease at the 51st Annual Symposium on Vascular and Endovascular
Simply Wall St.Insider Buyers At Humacyte Likely Disappointed With 17% Slide
Insiders who acquired US$775.1k worth of Humacyte, Inc.'s ( NASDAQ:HUMA ) stock at an average price of US$6.64 in the...
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.